A novel adjuvant Ling Zhi-8 for cancer DNA vaccines
Volume 7, Issue 11
Downloads and Tools
Pages 1161 - 1164http://dx.doi.org/10.4161/hv.7.11.17753
: DNA vaccine, LZ-8, adjuvant, cancer, dendritic cell, fungal immunomodulatory protein
Authors: Ching-Liang Chu, Dz-Chi Chen and Chi-Chen Lin View affiliations
DNA vaccines have a wide range of applications, with several potential advantages compared to other vaccine technologies for diseases. No DNA vaccine has yet been licensed in humans; however, a lot of effort has been made to enhance their potential as human vaccines and therapeutics. Finding an effective adjuvant is a strategy to improve the efficacy of DNA vaccines. We recently identified a fungal immunomodulatory protein Ling Zhi-8 (LZ-8) with stimulatory activity on dendritic cells (DCs) that significantly increases the efficacy of a cancer DNA vaccine in a preclinical tumor model, suggesting that LZ-8 may be a good candidate adjuvant for vaccine development. Here we discuss the possibility for applying LZ-8 to a cancer DNA vaccine for humans.
Received: August 8, 2011; Accepted: August 14, 2011